Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.C500138200 on April 29, 2005

J. Biol. Chem., Vol. 280, Issue 24, 22788-22792, June 17, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/24/22788    most recent
C500138200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, R.
Right arrow Articles by Zhao, Z. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, R.
Right arrow Articles by Zhao, Z. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of an Acquired JAK2 Mutation in Polycythemia Vera*

Runxiang Zhao{ddagger}, Shu Xing{ddagger}§, Zhe Li{ddagger}§, Xueqi Fu§, Qingshan Li§, Sanford B. Krantz{ddagger}, and Zhizhuang Joe Zhao{ddagger}§

From the {ddagger}Hematology/Oncology Division, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232 and the §Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun 130023, China

Polycythemia vera (PV) is a human clonal hematological disorder. The molecular etiology of the disease has not been identified. PV hematopoietic progenitor cells exhibit hypersensitivity to growth factors and cytokines, suggesting possible abnormalities in protein-tyrosine kinases and phosphatases. By sequencing the entire coding regions of cDNAs of candidate enzymes, we identified a G:C-> T:A point mutation of the JAK2 tyrosine kinase in 20 of 24 PV blood samples but none in 12 normal samples. The mutation has varying degrees of heterozygosity and is apparently acquired. It changes conserved Val617 to Phe in the pseudokinase domain of JAK2 that is known to have an inhibitory role. The mutant JAK2 has enhanced kinase activity, and when overexpressed together with the erythropoietin receptor in cells, it caused hyperactivation of erythropoietin-induced cell signaling. This gain-of-function mutation of JAK may explain the hypersensitivity of PV progenitor cells to growth factors and cytokines. Our study thus defines a molecular defect of PV.

Received for publication, March 25, 2005 , and in revised form, April 26, 2005.

* This work was supported by Grants HL076309 (to Z. J. Z.), DK-15555 (to S. B. K.), and CA-68485 (to Vanderbilt-Ingram Cancer Center) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: 777 Preston Research Bldg., 2220 Pierce Ave., Nashville, TN 37232. Fax: 615-936-3853; Tel.: 615-936-1797; E-mail: joe.zhao{at}vanderbilt.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
O. Abdel-Wahab, A. Mullally, C. Hedvat, G. Garcia-Manero, J. Patel, M. Wadleigh, S. Malinge, J. Yao, O. Kilpivaara, R. Bhat, et al.
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Blood, July 2, 2009; 114(1): 144 - 147.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Gery, Q. Cao, S. Gueller, H. Xing, A. Tefferi, and H. P. Koeffler
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
J. Leukoc. Biol., June 1, 2009; 85(6): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. Elliott, Y. Suessmuth, L. M. Scott, K. Nahlik, M. F. McMullin, S. N. Constantinescu, A. R. Green, and J. A. Johnston
SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
Haematologica, April 1, 2009; 94(4): 576 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez
High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms
J. Mol. Diagn., March 1, 2009; 11(2): 155 - 161.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Zeuner, F. Pedini, F. Francescangeli, M. Signore, G. Girelli, A. Tafuri, and R. De Maria
Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells
Blood, February 12, 2009; 113(7): 1522 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. Fourouclas, J. Li, D. C. Gilby, P. J. Campbell, P. A. Beer, E. M. Boyd, A. C. Goodeve, D. Bareford, C. N. Harrison, J. T. Reilly, et al.
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
Haematologica, November 1, 2008; 93(11): 1635 - 1644.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. V. Jones, N. C.P. Cross, H. E. White, A. R. Green, and L. M. Scott
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis
Haematologica, October 1, 2008; 93(10): 1560 - 1564.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Plo, M. Nakatake, L. Malivert, J.-P. de Villartay, S. Giraudier, J.-L. Villeval, L. Wiesmuller, and W. Vainchenker
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Blood, August 15, 2008; 112(4): 1402 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood, July 15, 2008; 112(2): 231 - 239.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Gakovic, J. Ragimbeau, V. Francois, S. N. Constantinescu, and S. Pellegrini
The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor
J. Biol. Chem., July 4, 2008; 283(27): 18522 - 18529.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S. G. Olthof, S. Fatrai, A. L. Drayer, M. R. Tyl, E. Vellenga, and J. J. Schuringa
Downregulation of Signal Transducer and Activator of Transcription 5 (STAT5) in CD34+ Cells Promotes Megakaryocytic Development, Whereas Activation of STAT5 Drives Erythropoiesis
Stem Cells, July 1, 2008; 26(7): 1732 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Blood, May 15, 2008; 111(10): 5109 - 5117.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Dusa, J. Staerk, J. Elliott, C. Pecquet, H. A. Poirel, J. A. Johnston, and S. N. Constantinescu
Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2
J. Biol. Chem., May 9, 2008; 283(19): 12941 - 12948.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M.-C. Blum, F. Breitenbuecher, S. Kasper, T. Kindler, R. L. Levine, C. Huber, et al.
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1176 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Blood, April 1, 2008; 111(7): 3863 - 3866.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al.
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Blood, April 1, 2008; 111(7): 3751 - 3759.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Ohyashiki, T. Kiguchi, Y. Ito, A. Gotoh, T. Tauchi, K. Miyazawa, Y. Kimura, H. Hisatomi, and J. H. Ohyashiki
Isolated Erythrocythemia: A Distinct Entity or a Sub-type of Polycythemia Vera?
Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 230 - 232.
[Full Text] [PDF]

Home page
 haematolHome page
L. Teofili, R. Foa, F. Giona, and L. M. Larocca
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Haematologica, February 1, 2008; 93(2): 169 - 172.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Verstovsek, T. Manshouri, A. Quintas-Cardama, D. Harris, J. Cortes, F. J. Giles, H. Kantarjian, W. Priebe, and Z. Estrov
WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation
Clin. Cancer Res., February 1, 2008; 14(3): 788 - 796.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Kirsammer, S. Jilani, H. Liu, E. Davis, S. Gurbuxani, M. M. Le Beau, and J. D. Crispino
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome
Blood, January 15, 2008; 111(2): 767 - 775.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. L. Levine and M. Heaney
New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia
Hematology, January 1, 2008; 2008(1): 76 - 82.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. J. Percy, L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones, A. R. Green, and M. F. McMullin
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
Haematologica, December 1, 2007; 92(12): 1607 - 1614.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, G. Leone, R. Foa, et al.
The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia
Blood, November 1, 2007; 110(9): 3384 - 3386.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. L. Chen and J. T. Prchal
X-linked clonality testing: interpretation and limitations
Blood, September 1, 2007; 110(5): 1411 - 1419.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Vickers
JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation
Blood, September 1, 2007; 110(5): 1675 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Teofili, M. Martini, T. Cenci, G. Petrucci, L. Torti, S. Storti, F. Guidi, G. Leone, and L. M. Larocca
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation
Blood, July 1, 2007; 110(1): 354 - 359.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood, June 15, 2007; 109(12): 5104 - 5111.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. B. Hookham, J. Elliott, Y. Suessmuth, J. Staerk, A. C. Ward, W. Vainchenker, M. J. Percy, M. F. McMullin, S. N. Constantinescu, and J. A. Johnston
The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Blood, June 1, 2007; 109(11): 4924 - 4929.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca
Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia
J. Clin. Oncol., March 20, 2007; 25(9): 1048 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao
Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
J. Biol. Chem., February 9, 2007; 282(6): 3428 - 3432.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard
Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation
J. Mol. Diagn., February 1, 2007; 9(1): 42 - 46.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al.
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
N. Engl. J. Med., February 1, 2007; 356(5): 459 - 468.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology, January 1, 2007; 2007(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao
JAK2V617F: prevalence in a large Chinese hospital population
Blood, January 1, 2007; 109(1): 339 - 342.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466.
[Full Text] [PDF]

Home page
 BloodHome page
P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al.
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Blood, November 15, 2006; 108(10): 3548 - 3555.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Ishii, E. Bruno, R. Hoffman, and M. Xu
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Blood, November 1, 2006; 108(9): 3128 - 3134.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Xiong, E. Liu, Y. Yan, R. T. Silver, F. Yang, I. H. Chen, Y. Chen, S. Verstovsek, H. Wang, J. Prchal, et al.
An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions
J. Immunol., October 1, 2006; 177(7): 4907 - 4916.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. M. Scott, M. A. Scott, P. J. Campbell, and A. R. Green
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Blood, October 1, 2006; 108(7): 2435 - 2437.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. H. Kurzer, P. Saharinen, O. Silvennoinen, and C. Carter-Su
Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State.
Mol. Cell. Biol., September 1, 2006; 26(17): 6381 - 6394.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek
Advances in the Therapy of Chronic Idiopathic Myelofibrosis
Oncologist, September 1, 2006; 11(8): 929 - 943.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Kralovics, S.-S. Teo, S. Li, A. Theocharides, A. S. Buser, A. Tichelli, and R. C. Skoda
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Blood, August 15, 2006; 108(4): 1377 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
T. Horn, M. Kremer, T. Dechow, W. M. Pfeifer, B. Geist, M. Perker, J. Duyster, L. Quintanilla-Martinez, and F. Fend
Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases
J. Mol. Diagn., July 1, 2006; 8(3): 299 - 304.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Walz, B. J. Crowley, H. E. Hudon, J. L. Gramlich, D. S. Neuberg, K. Podar, J. D. Griffin, and M. Sattler
Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition
J. Biol. Chem., June 30, 2006; 281(26): 18177 - 18183.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood, June 1, 2006; 107(11): 4214 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. T. Chung, A. J. Iafrate, P. C. Amrein, D. V. Sahani, and J. Misdraji
Case 15-2006 -- A 46-Year-Old Woman with Sudden Onset of Abdominal Distention
N. Engl. J. Med., May 18, 2006; 354(20): 2166 - 2175.
[Full Text] [PDF]

Home page
 BloodHome page
R. L. Levine, C. Belisle, M. Wadleigh, D. Zahrieh, S. Lee, P. Chagnon, D. G. Gilliland, and L. Busque
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis
Blood, May 15, 2006; 107(10): 4139 - 4141.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Walczak
Polycythemia vera erythroblasts: too tough to die
Blood, May 1, 2006; 107(9): 3422 - 3423.
[Full Text] [PDF]

Home page
 BloodHome page
F. Passamonti, E. Rumi, D. Pietra, M. G. D. Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, et al.
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
Blood, May 1, 2006; 107(9): 3676 - 3682.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Zeuner, F. Pedini, M. Signore, G. Ruscio, C. Messina, A. Tafuri, G. Girelli, C. Peschle, and R. De Maria
Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells
Blood, May 1, 2006; 107(9): 3495 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. V. Jones, R. T. Silver, K. Waghorn, C. Curtis, S. Kreil, K. Zoi, A. Hochhaus, D. Oscier, G. Metzgeroth, E. Lengfelder, et al.
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
Blood, April 15, 2006; 107(8): 3339 - 3341.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc., April 1, 2006; 81(4): 553 - 563.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ghaffari, C. Kitidis, W. Zhao, D. Marinkovic, M. D. Fleming, B. Luo, J. Marszalek, and H. F. Lodish
AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation
Blood, March 1, 2006; 107(5): 1888 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Sattler, C. Walz, B. J. Crowley, E. Lengfelder, P. A. Janne, A. M. Rogers, Y. Kuang, R. J. Distel, A. Reiter, and J. D. Griffin
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
Blood, February 1, 2006; 107(3): 1237 - 1238.
[Full Text] [PDF]

Home page
 BloodHome page
W. Zhao, C. Kitidis, M. D. Fleming, H. F. Lodish, and S. Ghaffari
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway
Blood, February 1, 2006; 107(3): 907 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
E. M. Adler, N. R. Gough, and L. B. Ray
2005: Signaling Breakthroughs of the Year
Sci. Signal., January 3, 2006; 2006(316): eg1 - eg1.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology, January 1, 2006; 2006(1): 233 - 239.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. Tefferi
Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era
Hematology, January 1, 2006; 2006(1): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Staerk, A. Kallin, J.-B. Demoulin, W. Vainchenker, and S. N. Constantinescu
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR
J. Biol. Chem., December 23, 2005; 280(51): 41893 - 41899.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek, M. Beran, E. Estey, H. M. Kantarjian, and J.-P. J. Issa
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
Blood, November 15, 2005; 106(10): 3370 - 3373.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Blood, November 15, 2005; 106(10): 3377 - 3379.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
M. Pesu, J. O'Shea, L. Hennighausen, and O. Silvennoinen
Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders
Mol. Interv., August 1, 2005; 5(4): 211 - 215.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
W. Vainchenker and S. N. Constantinescu
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases
Hematology, January 1, 2005; 2005(1): 195 - 200.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement